Measuring fertility could soon become as simple as using a tampon during your menstrual cycle. A research team from Federal Institute of Technology Zurich have developed a diagnostic device that analyzes menstrual blood to evaluate female ovarian reserve. The system is based on the detection of anti-Müllerian hormone (AMH), a fundamental biological indicator for understanding how many egg cells are still available in the ovaries.
Currently, finding out these values requires a venipuncture and specialized laboratory tests, procedures that not all women can afford on a regular basis. The new technology instead promises a completely different approach: no needles, no laboratories, just a discreet and repeatable check every month, from the comfort of home.
How the test works
The heart of the innovation lies in a lateral flow test, conceptually similar to common pregnancy tests or rapid swabs for COVID-19. The difference lies in the use of sophisticated nanotechnology, the system uses tiny 150 nanometer gold spheres, chemically modified to specifically bind to the anti-Müllerian hormone present in menstrual blood.
As the sample passes through the test strip, antibodies attached to the gold nanoparticles intercept the AMH molecules. This reaction produces a colored line whose intensity corresponds to the amount of hormone present. The higher the concentration of AMH, the darker the line appears, an immediate visual mechanism that translates complex biochemical data into information readable by the naked eye.
To eliminate margins of error in visual interpretation, researchers have also developed an artificial intelligence algorithm that can be used via smartphone. By photographing the test with your phone, the application automatically analyzes the color intensity and returns a precise semi-quantitative estimate of hormone levels, making the system accessible even to those without medical expertise.
Practical applications
The real revolution lies in the integration of this technology directly into menstrual hygiene products. The researchers demonstrated that the test can be incorporated into pads, turning them into passive diagnostic devices. During normal use, menstrual blood comes into contact with the reactive surface of the pad, automatically activating the analysis process.
This solution completely eliminates the need to collect or manipulate biological samples, making fertility monitoring a natural and discomfort-free gesture. For women who are planning a pregnancy or undergoing assisted reproduction treatments, it means being able to track the evolution of their ovarian reserve month after month, promptly identifying any significant changes.
The system could prove particularly valuable for young women who want to know their reproductive potential in advance, perhaps to make informed decisions about when to try to get pregnant. Likewise, it could help detect the approach of menopause early, giving women a wider time window to evaluate their choices.
Perspectives and limits
Despite the enthusiasm generated by the research, published as a pre-print on the platform medRxivsome open questions remain. Experts point out that AMH mainly indicates the quantity of available follicles, but does not provide direct information on their quality. A woman may have normal hormonal values but oocytes with less favorable characteristics for conception, especially as she ages.
Furthermore, there is debate about the actual usefulness of such frequent measurements when a single annual venipuncture could provide sufficient information for most women. The added value of continuous monitoring should be assessed on a case-by-case basis, considering that the ovarian reserve decreases gradually and does not undergo sudden changes from one month to the next.
The fact remains that this technology represents a significant step forward in the democratization of reproductive diagnostics, breaking down economic and logistical barriers that currently limit access to these checks. If further studies confirm its clinical reliability, we may see a transformation in the way women monitor and understand their reproductive health.
